Skip to main content

$0.062 0.002 (3.33%)

High

$0.06

Low

$0.06

Trades

18

Turnover

$32,113

Volume

526,676
30 June 2023 at 3:59pm
Register to track DXB and receive email alerts.
Subject
DXB Ann: Application for quotation of securities - DXB

DXB Ann: Application for quotation of securities - DXB

DXB Ann: Application for quotation of securities - DXB

DXB Ann: Application for quotation of securities - DXB

DXB Ann: Notification regarding unquoted securities - DXB

DXB Ann: Notification regarding unquoted securities - DXB

DXB Ann: Prospectus

DXB Ann: Results of Meeting

DXB Ann: Application for quotation of securities - DXB

DXB Ann: Change of Director's Interest Notices - NW and SP

DXB Ann: Change in substantial holding

DXB Ann: Dimerix to present at BIO International Convention

DXB Ann: Top 20 Option Holders & Distribution Schedule

DXB Ann: Notification regarding unquoted securities - DXB

DXB Ann: Application for quotation of securities - DXB

DXB Ann: Dimerix Announces Update on Successful Capital Raise

DXB Ann: Reminder of Closing Date for Non-Renounceable Rights Offer

DXB Ann: Application for quotation of securities - DXB

DXB Ann: Notification regarding unquoted securities - DXB

DXB Ann: Letter to Shareholders, Notice of Meeting & Proxy Form

DXB Ann: Letter to Ineligible Foreign Shareholders

DXB Ann: Letter to Nominees and Custodians

DXB Ann: Despatch of Prospectus and Letter to Eligible Shareholders

DXB Ann: Investor Webinar

DXB Ann: Rights Issue Prospectus

DXB Ann: Reinstatement to Official Quotation

DXB Ann: Investor Presentation

DXB Ann: Proposed issue of securities - DXB

DXB Ann: Proposed issue of securities - DXB

DXB Ann: Proposed issue of securities - DXB

DXB Ann: Proposed issue of securities - DXB

DXB Ann: Proposed issue of securities - DXB

DXB Ann: Proposed issue of securities - DXB

DXB Ann: Entitlement offer and Convertible Note to raise $12 million

DXB Ann: Voluntary Suspension

DXB Ann: Initial Director's Interest Notice - CS

DXB Ann: Dimerix Announces New Board Member

DXB Ann: Trading Halt

DXB Ann: Quarterly Appendix 4C and Activities Report

DXB Ann: Ceasing to be a substantial holder

DXB Ann: FSGS Study, Partnering & Commercialisation Investor Briefing

DXB Ann: Half-Year Financial Report & Appendix 4D - 31 December 2022

DXB Ann: DXB to Receive $2.8m in Prepayment of R&D Tax Incentive

DXB Ann: Successful Completion of DSMB Review of Phase 3 FSGS Trial

DXB Ann: Quarterly Appendix 4C and Activities Report

DXB Ann: FDA Confirms Inclusion of Paediatrics in ACTION3 Study

DXB Ann: Final Director's Interest Notice

DXB Ann: Resignation of Non-Executive Chairman

DXB Ann: DMX-200 FSGS Phase 3 Trial Part 1 Recruitment Achieved

DXB Ann: CLARITY 2.0 COVID-19 Study Outcome

Register to track DXB and receive email alerts.

Similar Companies

CSL ...
CSL
CUV
IMM
IMU
MSB
OPT
PAR
PYC
RAC
TLX